Cogentix Medical 10-K 30 May 14 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Mar. 31, 2014	30-May-14	Sep. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'VISION SCIENCES INC /DE/	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--03-31	'	'
Entity Common Stock, Shares Outstanding	'	47,531,859	'
Entity Public Float	'	'	$28,511,354
Amendment Flag	'false	'	'
Entity Central Index Key	'0000894237	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Mar-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net sales	$17,108	$15,287
Cost of sales	12,610	10,945
Gross profit	4,498	4,342
Selling, general, and administrative expenses	9,841	10,999
Research and development expenses	2,101	1,820
Operating loss	-7,444	-8,477
Interest income	1	4
Interest expense	-192	-503
Other, net	-24	-53
Debt cost expense	-43	-272
Loss on extinguishment of debt	'	-1,244
Loss before provision for income taxes	-7,702	-10,545
Income tax provision	12	12
Net loss	($7,714)	($10,557)
Net loss per common share - basic and diluted (in Dollars per share)	($0.17)	($0.23)
Weighted average shares used in computing net loss per common share - basic and diluted (in Shares)	46,155	45,945

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$1,237	$788
Accounts receivable, less allowances of $117 and $113, respectively	3,818	3,624
Inventories, net	4,194	5,158
Prepaid expenses and other current assets	455	276
Total current assets	9,704	9,846
Machinery and equipment	3,456	3,489
Demo equipment	1,311	1,101
Furniture and fixtures	225	225
Leasehold improvements	372	372
Property and equipment, at cost	5,364	5,187
Less—accumulated depreciation and amortization	4,302	3,733
Total property and equipment, net	1,062	1,454
Other assets, net	67	77
Total assets	10,833	11,377
Current liabilities:	'	'
Accounts payable	1,217	1,300
Accrued expenses	918	728
Accrued compensation	474	656
Deferred revenue	210	130
Capital lease obligations	22	75
Total current liabilities	2,841	2,889
Convertible debt—related party, net	22,414	17,000
Deferred revenue, net of current portion	93	62
Capital lease obligations, net of current portion	'	22
Total liabilities	25,348	19,973
Commitments and Contingencies	'	'
Stockholders’ deficit:	'	'
Common stock, $0.01 par value Authorized—75,000 shares; issued— 47,614 shares and 46,249 shares, respectively	476	463
Additional paid-in capital	102,629	100,819
Treasury stock at cost, 59 shares and 34 shares of common stock, respectively	-78	-50
Accumulated deficit	-117,542	-109,828
Total stockholders’ deficit	-14,515	-8,596
Total liabilities and stockholders’ deficit	$10,833	$11,377

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowances (in Dollars)	$117	$113
Preferred Stock Par Value (in Dollars per share)	$0.01	$0.01
Preferred Stock, Authorized Shares	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value (in Dollars per share)	$0.01	$0.01
Common Stock, Authorized Shares	75,000,000	75,000,000
Common Stock, Shares Issued	47,614,000	46,249,000
Treasury Stock, Shares	59,000	34,000

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders’ Deficit (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
In Thousands, except Share data
Balance at Mar. 31, 2012	$454	$98,382	($14)	($99,271)	($449)
Balance (in Shares) at Mar. 31, 2012	45,396,000	'	7,000	'	'
Exercise of stock options	1	98	'	'	99
Exercise of stock options (in Shares)	88,000	'	'	'	-87,881
Issuance of restricted stock awards (in Shares)	40,000	'	'	'	'
Cancellation of restricted stock awards (in Shares)	-50,000	'	'	'	'
Sale of common stock, net of fees of $122	6	872	'	'	878
Sale of common stock, net of fees of $122 (in Shares)	600,000	'	'	'	'
Issuance of commitment shares	2	-2	'	'	'
Issuance of commitment shares (in Shares)	175,000	'	'	'	'
Common stock repurchased	'	'	-36	'	-36
Common stock repurchased (in Shares)	'	'	27,000	'	'
Stock-based compensation expense	'	1,469	'	'	1,469
Net loss	'	'	'	-10,557	-10,557
Balance at Mar. 31, 2013	463	100,819	-50	-109,828	-8,596
Balance (in Shares) at Mar. 31, 2013	46,249,000	'	34,000	'	'
Issuance of restricted stock awards	13	-13	'	'	'
Issuance of restricted stock awards (in Shares)	1,365,000	'	'	'	'
Issuance of commitment shares (in Shares)	'	'	'	'	230,000
Common stock repurchased	'	'	-28	'	-28
Common stock repurchased (in Shares)	'	'	25,000	'	'
Beneficial conversion feature	'	1,129	'	'	1,129
Stock-based compensation expense	'	694	'	'	694
Net loss	'	'	'	-7,714	-7,714
Balance at Mar. 31, 2014	$476	$102,629	($78)	($117,542)	($14,515)
Balance (in Shares) at Mar. 31, 2014	47,614,000	'	59,000	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders’ Deficit (Parentheticals) (Additional Paid-in Capital [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013
Additional Paid-in Capital [Member]	'
Sale of common stock, net of fees	$122

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($7,714,000)	($10,557,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	695,000	795,000
Stock-based compensation expense	694,000	1,469,000
Debt cost expense	43,000	272,000
Provision for bad debt expenses	21,000	5,000
Loss on disposal of fixed assets	2,000	58,000
Loss on extinguishment of debt	'	1,244,000
Changes in assets and liabilities:	'	'
Accounts receivable	-215,000	-1,497,000
Inventories	692,000	-1,372,000
Prepaid expenses and other current assets	-179,000	-79,000
Other assets	10,000	'
Accounts payable	-83,000	713,000
Accrued expenses	190,000	-216,000
Accrued compensation	-182,000	-1,000
Deferred revenue	111,000	-86,000
Advances from customers	'	-394,000
Net cash used in operating activities	-5,915,000	-9,646,000
Cash flows from investing activities:	'	'
Purchases of property and equipment	-53,000	-95,000
Proceeds from disposal of fixed assets	3,000	5,000
Net cash used in investing activities	-50,000	-90,000
Cash flows from financing activities:	'	'
Proceeds from issuance of convertible debt—related party	6,500,000	2,000,000
Proceeds from promissory note—related party	'	5,000,000
Net proceeds from sale of common stock	0	878,000
Proceeds from exercise of stock options	'	99,000
Common stock repurchased	-28,000	-36,000
Payments of capital leases	-58,000	-91,000
Net cash provided by financing activities	6,414,000	7,850,000
Net increase (decrease) in cash and cash equivalents	449,000	-1,886,000
Cash and cash equivalents at beginning of period	788,000	2,674,000
Cash and cash equivalents at end of period	1,237,000	788,000
Cash paid during the period for:	'	'
Income taxes	11,000	17,000
Interest	8,000	592,000
Non-cash financing activities:	'	'
Beneficial conversion feature	1,129,000	'
Net transfers of inventory to fixed assets for use as demonstration equipment	272,000	184,000
Capital lease write-off	17,000	'
Debt consolidation	'	$15,000,000

Note_1_The_Company_and_Summary

Note 1 - The Company and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 1. The Company and Summary of Significant Accounting Policies
	Company Overview
	Vision-Sciences, Inc. and its subsidiaries (the “Company,” which may be referred to as “our”, “us”, or “we”) designs, develops, manufactures, and markets products for endoscopy – the science of using an instrument, known as an endoscope to provide minimally invasive access to areas not readily visible to the human eye. Our products are sold throughout the world through direct sales representatives in the United States (“U.S.”) and independent distributors for the rest of the world. With respect to our ureteroscope, we are the exclusive supplier to the Endoscopy Division of Stryker Corporation (“Stryker”). Our largest geographic markets are the U.S. and Europe.
	We were incorporated in Delaware, and are the successor to operations originally begun in 1987. In December 1990, Machida Incorporated (“Machida”) became our wholly-owned subsidiary. We own the registered trademarks Vision Sciences®, Slide-On®, EndoSheath®, EndoWipe® and The Vision System®. Not all products referenced in this report are approved or cleared for sale, distribution, or use.
	We have two reportable segments: medical and industrial. Each of these operating segments has unique characteristics and faces different opportunities and challenges.
	Our medical segment designs, manufactures and sells our advanced line of endoscopy-based products, including our flexible endoscopes, and our EndoSheath technology referred to as a sheath or EndoSheath disposable, for a variety of specialties and markets.
	Our industrial segment, through our wholly-owned subsidiary Machida, designs, manufactures, and sells borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers or a small camera for the visual inspection of narrow cavities.  Our borescopes are used to inspect aircraft engines, cast parts and ground turbines, among other items.
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate that we will continue to incur negative cash flows from operations during fiscal 2015, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, revitalizing a research and development pipeline, and general business operations. As of March 31, 2014, we had cash and cash equivalents totaling approximately $1.2 million. We expect that our cash at March 31, 2014, together with the $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2015, under a letter agreement dated May 29, 2014 from Lewis C. Pell, our Chairman, should be sufficient to fund our operations through at least March 31, 2015. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitment under the Letter Agreement becomes unavailable or expires, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vision-Sciences, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant of which relate to the allowance for doubtful accounts, market value for inventories, warranties, and fair value of equity based instruments. Actual results could differ from those estimates.
	Revenue Recognition
	We recognize revenue in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 605 (Topic 605, Revenue Recognition). ASC 605 requires that five basic criteria must be met before revenue can be recognized:
		1	persuasive evidence that an arrangement exists;
		2	delivery has occurred or services were rendered;
		3	the fee is fixed and determinable;
		4	collectability is reasonably assured; and
		5	the fair value of undelivered elements, if any, exists.
	Determination of criterion (4) above is based on management’s judgment regarding the collectability of invoices for products and services delivered to customers. Should changes in conditions cause management to determine this criterion is not met for certain future transactions, revenue recognized for any reporting period could be adversely affected. We recognize revenue when title passes to the customer, generally upon shipment of our products F.O.B. shipping point. Revenue for service repairs of equipment is recognized after service has been completed, and service contract revenue is recognized ratably over the term of the contract.
	For products sold to Stryker we recognize revenue in a two-step process. The first step is recognition of revenue for our cost to manufacture these products when title passes to Stryker, generally upon shipment of our products F.O.B. shipping point. The second step is recognition of revenue for our specified margin of Stryker’s gross profit after Stryker sells the products to its end customers, based upon reports received from Stryker monthly. There is no minimum amount of product that Stryker is required to purchase from us.
	Research and Development Expenses
	Costs of research, new product development, and product redesign are charged to expense as incurred.
	Stock-Based Compensation
	We account for stock-based awards issued to employees in accordance with the provisions of ASC 718 (Topic 718, Compensation – Stock Compensation). We recognize stock-based compensation expense on a straight-line uniform basis over the requisite service period of the award, which is generally four years for employees. We use historical data to estimate expected employee behaviors related to option exercises and forfeitures and include these expected forfeitures as a part of the estimate of stock-based compensation expense as of the grant date. For stock-based awards with performance-based vesting conditions, we are also required to estimate the probability of the vesting conditions being met. Stock-based awards issued to consultants are accounted for in accordance with the provisions of ASC 718 and ASC 505-50 (Subtopic 50 “Equity-Based Payments to Non-Employees” of Topic 505, Equity). Options granted to consultants are periodically revalued as the options vest, and are recognized as an expense over the related period of service or the vesting period, whichever is longer. Under the provisions of ASC 718, members of the Board are considered employees for calculation of stock-based compensation expense.
	Foreign Currency Transactions
	We charge foreign currency transaction gains or losses in connection with our purchases of products from foreign vendors to operations. For each of the fiscal years presented these amounts were immaterial.
	Income Taxes
	We account for income taxes in accordance with the provisions of ASC 740 (Topic 740, Income Taxes). ASC 740 prescribes that the use of the liability method be used for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized.
	ASC Topic 740 also clarifies the accounting for uncertainty in income taxes recognized in the financial statements. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return.
	Additionally, ASC Topic 740 provides guidance on the recognition of interest and penalties related to income taxes. We have elected to treat interest and penalties, to the extent they arise, as a component of selling, general, and administrative expenses.
	Basic and Diluted Net Loss per Common Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding. For all periods presented, the diluted net loss per common share is the same as basic net loss per common share, as the inclusion of other shares of stock issuable pursuant to stock options, warrants, and convertible debt would be anti-dilutive. The following table summarizes equity securities that were excluded from the calculation of fully diluted loss per share as of March 31, 2014 and 2013:
			March 31,
			2014			2013
	Convertible debt			20,599,250			14,166,667
	Stock options			4,377,874			5,780,608
	Warrants			1,880,620			1,880,620
	Restricted stock			1,325,402			122,044
	Total anti-dilutive securities			28,183,146			21,949,939
	Cash and Cash Equivalents
	We classify investments with original maturities of 90 days or less, consisting of certificates of deposits and a money market account at a bank, as cash equivalents. Cash and cash equivalents consisted of cash and money market accounts at March 31, 2014 and 2013.
	Fair Value Measurements
	The carrying amounts reflected in our consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses, accrued compensation, and capital lease obligations approximate fair value due to their short-term nature. The carrying value of our convertible debt-related party approximates fair value due to its attributes which include, amongst others, interest and its conversion feature into our common stock.
	In determining the fair value of the convertible debt – related party, we analyzed its attributes (coupon rate, conversion price, and the percentage of market cap the face value of the debt instrument was prior to the announcement of the debt) as compared to public company convertible debt issuances for an eleven (11) to sixteen (16) month period in the healthcare industry. We determined the convertible debt was not issued at a discount as its fair value was equal to its face (carrying) value.
	Allowance for Doubtful Accounts
	We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. This allowance is used to report trade receivables at estimated net realizable value. We rely on prior experience to estimate cash that ultimately will be collected from the gross receivables balance at period-end. We maintain a specific allowance for customer accounts that will likely not be collectible due to customer liquidity issues. We also maintain an allowance for estimated future collection losses on existing receivables, determined based on historical trends.
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivable relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.
	The following table summarizes net sales to our significant customers, which accounted for more than 10% of total segment net sales:
			Fiscal Year Ended March 31,
			2014			2013
	Medical segment
	Stryker		$	4,911		$	3,052
	Percentage of total segment net sales			35	%		26	%
	Percentage of total net sales			29	%		20	%
	Percentage of total accounts receivable, net			27	%		41	%
	Industrial segment
	Pratt & Whitney, a division of United Technology Corporation		$	527		$	944
	Percentage of total segment net sales			18	%		26	%
	Percentage of total net sales			3	%		6	%
	Percentage of accounts receivable, net			9	%		2	%
Inventories
Inventories are stated at the lower of cost or market using the first-in, first-out (“FIFO”) method. If cost exceeds market, inventory is reported at its estimated fair market value based upon our historical experience with inventory becoming obsolete due to age, changes in technology, and other factors. We record a write-down for inventories of components that have become obsolete, slow moving, or are in excess of anticipated demand or net realizable value. We perform a detailed review of inventory each fiscal quarter that considers multiple factors, including demand forecasts, product life cycle status, product development plans, and current sales levels. Inventories consist of the following:
		March 31,
		2014			2013
Raw materials		$	3,456		$	4,352
Work in process			329			427
Finished goods			409			379
Inventories, net		$	4,194		$	5,158
Raw materials include components purchased from independent suppliers. Most purchased components are available from multiple sources, with the exception of certain key components that are supplied to us by key suppliers, with whom we have long-term supply arrangements, but no long-term supply agreements.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Additions and improvements are capitalized, while maintenance and repairs are expensed as incurred. Asset and accumulated depreciation accounts are relieved for dispositions, with resulting gains or losses reflected in the statement of operations. Certain products used as sales demonstration and service loaner equipment are transferred from inventory to machinery and equipment and depreciated over 3 years.
Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives of the various assets, or for leasehold improvements, over the term of the lease, if shorter. The estimated useful lives for each major asset classification are as follows:
Asset Classification		Estimated Useful Life
Machinery and equipment		7 - 15 years
Demo equipment		3 years
Furniture and fixtures		5 years
Leasehold improvements		lesser of lease period or 10 years
Intangible assets		6 - 15 years
Depreciation and amortization expense was $695 thousand and $795 thousand in fiscal years 2014 and 2013, respectively.
Other Assets
Other assets consist primarily of deposits and patents. Patents are amortized on a straight-line basis over a period of up to 15 years. Our patents became fully amortized during the fiscal year ended March 31, 2012.
Long-Lived Assets
We review the carrying values of our long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. We believe that the carrying value of these assets is fully realizable at March 31, 2014 and 2013.
Deferred Debt Cost
We defer costs, including the fair value of commitment warrants, associated with securing a line of credit or revolving loan agreement over the applicable term to maturity of the agreement. These costs are amortized as debt cost expense in our consolidated statement of operations. The costs are amortized over the term of the line of credit or revolving loan agreement on a straight-line basis or using the effective interest method.
The following table summarizes the components of gross and net deferred debt cost balances as of March 31, 2013, which was fully amortized upon the extinguishment of the debt in fiscal 2013:
		March 31,
Deferred debt cost		2014			2013
Gross carrying amount		$	-		$	2,060
Accumulated amortization			-			(816	)
Extinguishment of debt			-			(1,244	)
Net carrying amount		$	-		$	-
Beneficial Conversion Feature
We account for potentially beneficial conversion features in accordance with the provisions of ASC 470-20 (Subtopic 20 “Debt with Conversions and Other Options” of Topic 470, Debt). A beneficial conversion feature exists if the fair value of the underlying common stock increases above the conversion price of the instrument on the commitment date. The difference in the common stock and conversion prices potentially results in a benefit conversion feature, a nondetachable conversion feature that is in the money at the commitment date. This resulting benefit is recorded as a convertible debt discount, with a corresponding increase to additional paid-in capital, and amortized using the effective interest method over the period from the commitment date (borrowing date) to the maturity date of the convertible debt.
Warranty Obligations
We provide warranty on all of our products. We estimate the costs that may be incurred under warranties and record a liability in the amount of such costs at the time the product is sold. Factors that affect our warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and cost per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Warranty expense is recorded in cost of sales in our statement of operations.
The following table summarizes changes in our warranty reserve for fiscal years 2014 and 2013:
		March 31,
		2014			2013
Warranty reserve at April 1		$	280		$	303
Warranties accrued during the fiscal year			60			230
Warranties settled during the fiscal year			(110	)		(253	)
Warranty reserve at March 31		$	230		$	280
The warranty reserve at March 31, 2014 and 2013 is included in accrued expenses in our consolidated balance sheets.

Note_2_Segment_Information

Note 2 - Segment Information	12 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 2. Segment Information
	We design, develop, manufacture, and market products for endoscopy in two reportable segments: medical and industrial.
	Management evaluates the revenue and profitability performance of each of our segments to make operating and strategic decisions. We have no intersegment revenue.
	Fiscal Year Ended March 31,	Medical			Industrial			Adjustments*			Consolidated
	2014
	Net sales	$	14,133		$	2,975		$	-		$	17,108
	Gross profit		3,469			1,029			-			4,498
	Operating loss		(7,435	)		(9	)		-			(7,444	)
	Depreciation and amortization		684			11			-			695
	Assets		11,243			1,775			(2,185	)		10,833
	Expenditures for fixed assets		53			-			-			53
	2013
	Net sales	$	11,630		$	3,657		$	-		$	15,287
	Gross profit		3,102			1,240			-			4,342
	Operating loss		(8,381	)		(96	)		-			(8,477	)
	Depreciation and amortization		772			23			-			795
	Assets		11,833			1,466			(1,922	)		11,377
	Expenditures for fixed assets		95			-			-			95
		March 31,
	*Adjustments	2014			2013
	Intercompany eliminations	$	(1,499	)	$	(1,236	)
	Investment in subsidiaries		(686	)		(686	)
	Total adjustments	$	(2,185	)	$	(1,922	)
	The following table presents the reconciliation of loss before provision for income taxes:
		Fiscal Year Ended March 31,
		2014			2013
	Operating loss	$	(7,444	)	$	(8,477	)
	Interest expense, net		(191	)		(499	)
	Debt cost expense		(43	)		(272	)
	Loss on extinguishment of debt		-			(1,244	)
	Other, net		(24	)		(53	)
	Loss before provision for income taxes	$	(7,702	)	$	(10,545	)
	The following table presents net sales based on the geographic location of the external customer. The United Kingdom accounted for 14% of our worldwide net sales in fiscal 2014. No individual foreign country accounted for more than 10% of our worldwide net sales in fiscal 2013.
		Fiscal Year Ended March 31,
		2014						2013
	United States	$	11,435			67	%	$	10,296			67	%
	Europe		4,642			27	%		3,527			23	%
	Asia and Australia		349			2	%		345			2	%
	Canada		274			2	%		471			3	%
	Middle East and Africa		254			1	%		468			3	%
	Central and South America		154			1	%		180			2	%
	Net sales	$	17,108			100	%	$	15,287			100	%

Note_3_Income_Taxes

Note 3 - Income Taxes	12 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 3. Income Taxes
	We account for income taxes in accordance with ASC 740 (Topic 740, Income Taxes). ASC 740 is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected tax consequences or events that have been recognized in our financial statements or tax returns. ASC Topic 740 also clarifies the accounting for uncertainty in income taxes recognized in the financial statements. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. There were no significant matters determined to be unrecognized tax benefits taken or expected to be taken in a tax return that have been recorded in our consolidated financial statements for fiscal years 2014 and 2013.
	Additionally, ASC Topic 740 provides guidance on the recognition of interest and penalties related to income taxes. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for fiscal years 2014 and 2013. We have elected to treat interest and penalties, to the extent they arise, as a component of selling, general, and administrative expenses in our consolidated statement of operations.
	In fiscal years 2014 and 2013, we recorded an income tax provision of approximately $12 thousand for minimum state taxes.
	The reconciliation of the effective income tax rate to the federal statutory rate is as follows:
		Fiscal Year Ended March 31,
		2014			2013
	Federal statutory rate		-34	%		-34	%
	State taxes, net of federal tax benefit		-6	%		--	%
	Permanent differences:
	Incentive stock options		2	%		2	%
	Effect of permanent differences		2	%		2	%
	Increase in valuation allowance		38	%		32	%
	Effective tax rate		--	%		--	%
	As of March 31, 2014, we had approximately $72.7 million of federal net operating loss carryforwards in the U.S. These net operating loss carryforwards expire at various dates through our fiscal 2034, commencing in fiscal 2015. As of March 31, 2014, we had approximately $45.7 million of state net operating loss carryforwards in the U.S. These net operating loss carryforwards expire at various dates through our fiscal 2029, commencing in fiscal 2015. We had $1.7 million state net operating loss carryforwards expire in fiscal 2014.
	The IRC limits the amounts of net operating loss carryforwards that a company may use in any one year in the event of certain cumulative changes in ownership over a three-year period as described in Section 382 of the IRC. We have not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership could limit our utilization of the net operating losses, and could be triggered by subsequent sales of securities by us or our stockholders.
	The tax effects of the major items recorded as deferred tax assets are as follows:
		March 31,
		2014			2013
	Net operating loss carryforwards	$	26,884		$	24,310
	Stock-based compensation		3,136			2,898
	Nondeductible reserves		224			248
	Depreciation and amortization		208			143
	Capital loss carryforwards		7			7
	Other		366			352
	Gross deferred tax asset		30,825			27,958
	Valuation allowance		(30,825	)		(27,958	)
	Net deferred tax asset	$	-		$	-
	The ending balances of the deferred tax asset have been fully reserved, reflecting the uncertainties as to realizability evidenced by our historical results and restrictions on the usage of the net operating loss carryforwards. We increased the valuation allowance by $2.9 million in fiscal 2014 to account for the change in the gross deferred tax asset.
	We file tax returns in the U.S. federal jurisdiction and various states. We are no longer subject to U.S. federal tax examinations for years before our fiscal 2010 with exception of the net operating losses, for which the statute of limitations will expire the earlier of three years after the utilization or when expired. State jurisdictions that remain subject to examination range from our fiscal year 2011 to 2013.

Note_4_Accrued_Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 4. Accrued Expenses
	The following table shows our consolidated financial statement details as of March 31, 2014 and 2013:
		March 31,
		2014		2013
	Interest payable—related party	$	253	$	70
	Warranty reserve		230		280
	Accrued accounts payable		108		63
	Accrued other		96		75
	Accrued accounting fees		90		100
	Accrued legal fees		77		41
	Sales tax payable		33		27
	Accrued travel expenses		31		72
	Accrued expenses	$	918	$	728

Note_5_Supply_Agreement

Note 5 - Supply Agreement	12 Months Ended
	Mar. 31, 2014
Deferred Revenue Disclosure [Abstract]	'
Deferred Revenue Disclosure [Text Block]	'
	Note 5. Advances from Customers
	Supply Agreements
	We are the exclusive supplier of the following Stryker-branded flexible endoscopes and co-branded EndoSheath technology:
	Market	Product	Term
	Urology	URT-7000 Video Ureteroscope	3-year agreement (December 2012 - December 2015)
		CST-5000 Video Cystoscope	3-year agreement (April 2011 - May 2014)
		CST-4000 Fiber Cystoscope	3-year agreement (April 2011 - May 2014)
		EndoSheath technology (cystoscopy only)	3-year agreement (April 2011 - May 2014)
		Peripherals and accessories (ureteroscopy)	3-year agreement (December 2012 - December 2015)
		Peripherals and accessories (cystoscopy)	3-year agreement (April 2011 - May 2014)
	Stryker has the exclusive rights to distribute our ureteroscope worldwide.
	Stryker wanted to extend its rights to market and sell our cystoscope and EndoSheath technology product lines beyond May 2014; however, we decided to sell direct in the U.S. in order to maximize revenue and margins. We made this decision in large part because Stryker’s endoscopy direct sales force is focused on the operating room in hospitals, while most cystoscopy procedures are performed in physicians’ offices and ambulatory surgical centers. We believe our U.S. sales force will be able to maximize revenue potential by focusing on these call points (physicians’ offices and ambulatory surgical centers).
	We received advances from our strategic partners for future orders and for an initial stocking order. All of the advances were fully utilized as of March 31, 2013.

Note_6_Convetible_Debt_Related

Note 6 - Convetible Debt - Related Party	12 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 6. Convertible Debt – Related Party
	Convertible Promissory Notes
	The following table is a summary of our convertible debt – related party at March 31, 2014:
	Convertible Debt—Related Party	Gross		Unamortized			Net
		Principal		Debt			Amount
		Amount		Discount			Outstanding
		Outstanding
	Replacement Note	$	20,000	$	-		$	20,000
	2013 Note		3,500		(1,086	)		2,414
		$	23,500	$	(1,086	)	$	22,414
	On September 25, 2013 (the “Effective Date”), we entered into a $3.5 million revolving convertible promissory note (the “2013 Note”) with Mr. Pell. The 2013 Note accrues annual interest, payable annually, at the rate of 1.66%. The 2013 Note must be repaid in full on or before the fifth anniversary of the Effective Date (the “Maturity Date”), but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the 2013 Note upon an event of default, as defined in the 2013 Note. The outstanding principal amount of the 2013 Note is convertible at any time prior to the Maturity Date, at Mr. Pell’s option, into shares of our common stock at a price of $0.89, the closing bid price of our common stock on the Effective Date. At March 31, 2014, we had outstanding principal borrowings of $3.5 million, gross of the amount recognized as a beneficial conversion feature, under the 2013 Note, which is reflected as convertible debt – related party on our consolidated balance sheet.
	During each draw upon the 2013 Note, a beneficial conversion feature was recorded as a result of the market price of our common stock increasing after the Effective Date. The following table summarizes the beneficial conversion feature amounts recorded as of March 31, 2014:
	Date	Borrowing		Convertible			Share		Gross
		Amount		Shares			Price on		Beneficial
							Borrowing		Conversion
							Date		Feature
	7-Oct-13	$	1,000		1,123,595		$	0.95	$	67
	26-Nov-13		1,000		1,123,595			1.01		135
	21-Jan-14		1,000		1,123,595			1.39		562
	13-Mar-14		500		561,799			1.54		365
		$	3,500		3,932,584				$	1,129
	The beneficial conversion feature amounts were recorded as a convertible debt discount with a corresponding increase to additional paid-in capital. The amounts are being amortized using the effective interest rate method over a five-year period from the borrowing date to the Maturity Date. At March 31, 2014, the unamortized convertible debt discount balance was $1.1 million and is expected to be recognized over a period of approximately 4.5 years.
	On September 19, 2012 (the “Replacement Note Effective Date”), we entered into a $20.0 million revolving convertible promissory note (the “Replacement Note”) with Mr. Pell. The Replacement Note (i) consolidated and restructured the $15.0 million in aggregate borrowings collectively outstanding under an Amended and Restated Loan Agreement, dated September 30, 2011, between us and Mr. Pell (the “Original Agreement”) and a separate promissory note, dated July 25, 2012, between us and Mr. Pell, and (ii) provided for up to $5.0 million in additional borrowings.
	The Replacement Note accrues annual interest, payable annually, at the rate of 0.84%. The Replacement Note must be repaid in full on or before the fifth anniversary of the Replacement Note Effective Date (the “Replacement Note Maturity Date”), but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the Replacement Note upon an event of default, as defined in the Replacement Note.
	The outstanding principal amount of the Replacement Note is convertible at any time prior to the Replacement Note Maturity Date, at Mr. Pell’s option, into shares of our common stock at a conversion price of $1.20 per share, which was the closing bid price of our common stock on the Replacement Note Effective Date. At March 31, 2014, we had $20.0 million in outstanding principal borrowings under the Replacement Note, which is reflected as convertible debt – related party on our consolidated balance sheet.
	Pursuant to the Original Agreement, Mr. Pell received warrants to purchase an aggregate of 1,880,620 shares of our common stock at a weighted average exercise price of $1.86 per share. All of the warrants are vested and expire on the later of September 30, 2016 or one year after the termination of the Original Agreement and repayment of all amounts due and payable under the Original Agreement.
	In connection with the issuance of the Replacement Note and the termination of the Original Agreement, we determined that the transaction should be classified as an extinguishment of debt. Accordingly, we wrote-off the remaining deferred debt cost balance of $1.2 million at September 19, 2012.
	We estimated the fair value of all of the stock warrants issued on the date of vesting using a Black-Scholes valuation model that used the weighted average assumptions for the risk-free interest rate, expected life (in years), and expected volatility. We recorded the transaction as a deferred debt cost and amortized to expense over the term of the loan.
	Debt cost expense related to the amortization of the convertible debt discount and interest expense related to the accrued interest on outstanding borrowings for fiscal years 2014 and 2013 were recorded in our consolidated statement of operations as follows:
		Fiscal Year Ended
		March 31,
		2014		2013
	Debt cost expense	$	43	$	272
	Interest expense		183		488
	At March 31, 2014, we had an aggregate amount of $253 thousand in accrued interest under the Replacement Note and the 2013 Note, which is included in accrued expenses on our consolidated balance sheet.
	Letter Agreement
	Pursuant to the Letter Agreement, Mr. Pell has agreed to provide financial assistance to us in the amount of up to $5.0 million, if necessary to support our operations, for a period ending on the earlier of (i) July 1, 2015 or (ii) our raising debt or equity capital in the amount of $5.0 million or more. This financial assistance, if drawn by us, would be in the form of an additional loan, share purchase, or financing transaction, on such terms as we and Mr. Pell may determine. We have not utilized the financial assistance agreement.

Note_7_Commitments_and_Conting

Note 7 - Commitments and Contingencies	12 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 7. Commitments and Contingencies
	Leases
	We rent our facilities in Orangeburg, NY (“Orangeburg”) and Natick, MA (“Natick”) from non-related parties. We occupy 20,500 square feet in our facility in Orangeburg under a lease, amended in April 2009, which expires in August 2015. Our Natick facility occupies 9,835 square feet under a lease, amended in January 2014, which expires in August 2015. We also lease some office and production equipment under leases that expire in August 2014.
	The following table summarizes the future minimum lease commitments under all operating and capital leases as of March 31, 2014:
	Fiscal Year Ending March 31,	Office		Capital
		Lease		Lease
		Commitments		Obligations
	2015	$	471	$	22
	2016		196		-
	Total future minimum lease payments	$	667		22
	Less—amount representing interest				-
	Present value of future payments			$	22
	Total rent expense was approximately $488 thousand and $496 thousand in fiscal years 2014 and 2013, respectively. Certain of our leases contain purchase and/or renewal options.
	Litigation
	As of March 31, 2014, we had no material legal proceedings to which we, or any of our subsidiaries, are a party or to which any of our properties are subject.

Note_8_Common_Stock

Note 8 - Common Stock	12 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 8. Common Stock
	On April 27, 2012, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which we have the right to sell to LPC up to $15.0 million in shares of our common stock from time-to-time over a period of up to three years, subject to certain limitations and conditions set forth in the Purchase Agreement. This total maximum amount of $15.0 million would increase to $21.0 million if the aggregate market value of shares of our common stock held by non-affiliates reached at least $75.0 million during the three-year term of the Purchase Agreement. The Purchase Agreement contains customary representations, warranties and agreements between us and LPC, limitations (market price of our common stock and LPC’s ownership limit) and conditions to completing future sale transactions, indemnification rights and other obligations of the parties. In connection with the initial purchase under the Purchase Agreement, and any future sales under the Purchase Agreement, Mr. Pell waived the repayment requirement under the Loan Agreement. On July 26, 2012, we amended the Purchase Agreement with LPC to, among other things, create a threshold price of $3.00 for the sale of our common stock to LPC, as calculated pursuant to the formula provided in the Purchase Agreement.
	As consideration for entering into the Purchase Agreement and for their initial purchase of $1.0 million of our common stock in April 2012, we issued to LPC 175,333 shares of our common stock. As consideration for any remaining future purchases under the Purchase Agreement, we also will issue to LPC, on a pro rata basis in connection with each purchase of shares by LPC, up to a total of approximately 215,000 additional shares of our common stock. We did not receive any cash proceeds from the issuance of 175,333 shares and will not receive any proceeds upon the issuance of any of the remaining 215,000 shares.
	The following table summarizes the common stock issued and cash received in connection with the Purchase Agreement:
	Month		Description	Number of		Share		Gross
				Shares of		Price		Proceeds
				Common Stock
				Issued
	Apr-12		Initial purchase shares		599,880	$	1.667	$	1,000
	Apr-12		Initial commitment shares		160,000		-		-
	Apr-12		Initial additional commitment shares (1)		15,333		-		-
					775,213			$	1,000
		-1	Calculated as follows: ($1.0 million stock purchase divided by $15.0 million total maximum amount) multiplied by 230,000 additional commitment shares.
	In connection with the Purchase Agreement, we incurred $122 thousand of costs associated with investment banking fees, legal fees, and expense reimbursement to LPC. Our net proceeds from the sale of the initial purchase shares were $878 thousand in fiscal 2013. No amounts have been received under the Purchase Agreement in fiscal 2014.

Note_9_StockBased_Awards

Note 9 - Stock-Based Awards	12 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 9. Stock-Based Awards
	We maintain the following stockholder-approved equity incentive plans:
		●	The 2000 Stock Incentive Plan (the “2000 Plan”) authorized the issuance of up to 4,500,000 shares of common stock covering several different types of awards, including stock options, restricted shares, stock appreciation rights, and performance shares.
		●	The 2007 Stock Incentive Plan (the “2007 Plan”) authorized the issuance of up to 5,000,000 shares of common stock covering several different types of awards, including stock options, restricted shares, stock appreciation rights, and other stock-based awards. On July 26, 2012, our stockholders approved an amendment to the 2007 Plan further increasing the number of authorized shares issuable under the plan to 7,000,000 shares of common stock.
		●	The 2003 Director Option Plan (the “2003 Plan”) authorized the issuance of up to 450,000 shares of common stock covering the annual automatic grant, unless waived, of 10,000 stock options per outside director per year. The 2003 Plan also provides for granting newly elected or appointed outside directors a one-time grant of 10,000 stock options.
	The stock option plans provide that options may be granted at an exercise price of 100% of fair market value of our common stock on the date of grant, may be exercised in full or in installments, at the discretion of our Board of Directors (the “Board”) or its Compensation Committee (the “Compensation Committee”), and must be exercised within ten years from date of grant. We recognize stock-based compensation expense on a straight-line basis over the requisite service period based on fair values, generally four years. We use historical data to estimate expected employee behaviors related to option exercises and forfeitures and included these expected forfeitures as a part of the estimate of stock-based compensation expense as of the grant date.
	Stock Options
	The following table summarizes stock option activity for fiscal years 2014 and 2013:
			Fiscal Year Ended March 31,
			2014								2013
			Number				Weighted				Number				Weighted
			of Shares				Average				of Shares				Average
							Exercise								Exercise
							Price								Price
	Outstanding at April 1			5,780,608			$	2.09				6,007,661			$	2.23
	Granted			1,096,500				1.04				1,019,750				1.25
	Exercised			-				-				(87,881	)			1.13
	Cancelled (1)			(2,499,234	)			2.19				(1,158,922	)			2.18
	Outstanding at March 31			4,377,874			$	1.78				5,780,608			$	2.09
	Vested and expected to vest at March 31			4,302,138			$	1.79				5,622,126			$	2.1
	Exercisable at March 31			3,531,403			$	1.9				3,580,173			$	2.34
	(1) Includes cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari (1,125,000 stock options), and our former EVP, Corporate Development and Chief Financial Officer, Katherine L. Wolf (612,458 stock options).
	At March 31, 2014, there were 1,415,603 shares of common stock reserved for stock options. We generally issue shares for the exercise of stock options from unissued reserved shares.
	The weighted average remaining contractual term was approximately 6.0 years for stock options outstanding, approximately 5.3 years for stock options exercisable, and 5.9 years for stock options vested and expected to vest as of March 31, 2014. The weighted average fair value of options granted was $0.68 and $0.90 in fiscal years 2014 and 2013, respectively.
	The total intrinsic value (the excess of the market price over the exercise price) was approximately $319 thousand for stock options outstanding, $202 thousand for stock options exercisable, and $308 thousand for stock options vested and expected to vest as of March 31, 2014. The total intrinsic value for stock options exercised was approximately $25 thousand in fiscal 2013. There were no stock options exercised during fiscal 2014.
	We do not expect to realize any tax benefits from future disqualifying dispositions, if any, because we currently have a full valuation allowance against our deferred tax assets.
	The following table summarizes information concerning outstanding and exercisable stock options at March 31, 2014:
						Stock Options Outstanding											Stock Options Exercisable
	Range of Exercise Prices					Number				Weighted				Weighted			Number		Weighted
						of Shares				Average				Exercise			of Shares		Average
										Remaining				Average					Exercise
										Contractual Life				Price					Price
	$0.79	-	$1.16				1,591,250				8.07			$	1			994,500	$	1
	$1.17	-	$2.32				1,868,399				4.88			$	1.64			1,710,586	$	1.62
	$2.33	-	$3.48				464,350				6.63			$	2.63			372,442	$	2.65
	$3.49	-	$4.65				293,375				1.23			$	3.93			293,375	$	3.93
	$4.66	-	$5.81				160,500				4.16			$	4.88			160,500	$	4.88
							4,377,874				5.96			$	1.78			3,531,403	$	1.9
	Restricted Stock
	We determine stock-based compensation expense for performance based restricted stock based upon the fair value of our common stock at the date of grant and recognize expense based upon the most probable outcome as to whether the performance targets will be achieved and the stock-based compensation being earned.
	The following table summarizes restricted stock activity for fiscal years 2014 and 2013:
			Fiscal Year Ended March 31,
			2014								2013
							Weighted								Weighted
							Average								Average
			Number				Grant				Number				Grant
			of Shares				Price				of Shares				Price
	Nonvested at April 1			122,044			$	2.37				306,606			$	2.5
	Granted			1,365,000				1				40,000				1.4
	Vested			(161,642	)			1.54				(174,284	)			2.3
	Forfeited			-				-				(50,278	)			2.66
	Nonvested at March 31			1,325,402			$	1.06				122,044			$	2.37
	We grant restricted stock awards (“RSA’s”) to our executive officers and management employees (collectively “management”) and members of our Board from time-to-time. There is no direct cost to the recipients of the RSA’s, except for any applicable taxes upon lapsing of the restrictions. In fiscal 2011, the Compensation Committee adopted a performance incentive plan (“PIP”) that provides for the payment of bonuses to management based on the attainment of specified Company performance and individual objectives. Any payments that may be due under the PIP will be paid in shares of restricted stock awarded under our 2007 Plan. The Compensation Committee did not approve a PIP for fiscal 2014 or 2013.
	On November 26, 2013 (the “Appointment Date”), at the time of his appointment as President and Chief Executive Officer, Howard Zauberman was granted 1,200,000 shares of restricted stock. The restrictions on Mr. Zauberman’s restricted stock will lapse over four years (subject to further vesting as described below) commencing on the Appointment Date as follows: up to 300,000 shares become unrestricted each year, upon Mr. Zauberman’s achievement of predetermined Company milestones and individual performance objectives (the “Milestones”) based on a plan developed by Mr. Zauberman and approved by the Board on April 23, 2014 (the “Plan”). If a Milestone is not achieved, the shares of restricted stock tied to that Milestone are cancelled. Those restricted shares for which restrictions have been removed as a result of Mr. Zauberman’s achieving Milestones as described above will then vest in four equal annual installments.
	Stock-Based Compensation Expense
	We estimated the fair value of the stock options granted on the date of grant using a Black-Scholes valuation model that used the weighted average assumptions noted in the following table. The risk-free interest rate assumption we use is based upon United States Treasury interest rates appropriate for the expected life of the awards. The expected life (estimated period of time that we expect employees, consultants and directors to hold their stock options) was estimated based on historical rates for two group classifications, (i) employees and consultants and (ii) outside directors. Expected volatility was based on historical volatility of our stock price for a period equal to the stock option’s expected life and calculated on a daily basis. The expected dividend rate is zero since we do not currently pay cash dividends on our common stock and do not anticipate doing so in the foreseeable future.
			Fiscal Year Ended March 31,
			2014				2013
	Risk-free interest rate			1.27	%			1.05	%
	Expected life (in years)			5.47				6.43
	Expected volatility			79	%			84	%
	Expected dividend yield			--				--
	The following table summarizes stock-based compensation recorded in our consolidated statements of operations in fiscal years 2014 and 2013:
		Fiscal Year Ended March 31,
		2014				2013
Cost of sales		$	54			$	89
Selling, general, and administrative expenses(1)			577				1,329
Research and development expenses			63				51
Total stock-based compensation		$	694			$	1,469
(1) Reflects reversal of stock-based compensation expense of $289 thousand in fiscal 2014 for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.
At March 31, 2014, unrecognized stock-based compensation expense related to stock options was approximately $0.5 million and is expected to be recognized over a weighted average period of approximately 2.5 years. At March 31, 2014, unrecognized stock-based compensation expense related to nonvested (restricted stock) awards was approximately $0.1 million, which is expected to be recognized over a weighted average period of approximately 0.6 years.

Note_10_Treasury_Stock

Note 10 - Treasury Stock	12 Months Ended
	Mar. 31, 2014
Disclosure Text Block Supplement [Abstract]	'
Treasury Stock [Text Block]	'
	Note 10. Treasury Stock
	The following table summarizes treasury stock activity for fiscal years 2014 and 2013:
		Number				Weighted
		of Shares				Average
	Fiscal Year Ended	Repurchased		Cost		Purchase Price
	31-Mar-14		25,525	$	28	$	1.11
	31-Mar-13		27,329	$	36	$	1.32
	The shares were purchased from management employees to cover income tax withholdings upon the lapse of restrictions on their restricted stock awards. Although not required to under our equity incentive plans, we anticipate repurchasing shares in a similar arrangement during fiscal 2015.

Note_11_Employee_Savings_Plan

Note 11 - Employee Savings Plan	12 Months Ended
	Mar. 31, 2014
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	Note 11. Employee Savings Plan
	We have a savings plan in the U.S. that qualifies under Section 401(k) of the Internal Revenue Code (“IRC”). Participating U.S. employees may contribute up to 70% of their salary, but not more than statutory limits. We may, but are not obligated to, make a matching contribution up to a certain percentage of each employee’s contribution. Matching contributions are invested proportionate to each participant’s voluntary contributions in the investment options provided under the plan. We did not make any matching contributions in fiscal years 2014 and 2013.

Note_12_Quarterly_Financial_Da

Note 12 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Mar. 31, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	Note 12. Quarterly Financial Data (Unaudited)
		Fiscal Year Ended March 31, 2014
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter			Total
	Net sales	$	3,652		$	3,968		$	4,507		$	4,981		$	17,108
	Gross profit	$	1,080		$	1,195		$	1,378		$	845		$	4,498
	Net loss	$	(2,434	)	$	(1,323	)	$	(1,562	)	$	(2,395	)	$	(7,714	)
	Net loss per common share - basic and diluted	$	(0.05	)	$	(0.03	)	$	(0.03	)	$	(0.05	)	$	(0.17	)
		Fiscal Year Ended March 31, 2013
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter			Total
	Net sales	$	3,396		$	3,739		$	3,952		$	4,200		$	15,287
	Gross profit	$	913		$	1,070		$	1,132		$	1,227		$	4,342
	Net loss	$	(2,647	)	$	(4,264	)	$	(1,577	)	$	(2,069	)	$	(10,557	)
	Net loss per common share - basic and diluted	$	(0.06	)	$	(0.09	)	$	(0.03	)	$	(0.04	)	$	(0.23	)

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies) (USD $)	12 Months Ended
	Mar. 31, 2014								Mar. 31, 2013
Accounting Policies [Abstract]	'								'
Basis of Accounting, Policy [Policy Text Block]	'								'
	Vision-Sciences, Inc. and its subsidiaries (the “Company,” which may be referred to as “our”, “us”, or “we”) designs, develops, manufactures, and markets products for endoscopy – the science of using an instrument, known as an endoscope to provide minimally invasive access to areas not readily visible to the human eye. Our products are sold throughout the world through direct sales representatives in the United States (“U.S.”) and independent distributors for the rest of the world. With respect to our ureteroscope, we are the exclusive supplier to the Endoscopy Division of Stryker Corporation (“Stryker”). Our largest geographic markets are the U.S. and Europe.
	We were incorporated in Delaware, and are the successor to operations originally begun in 1987. In December 1990, Machida Incorporated (“Machida”) became our wholly-owned subsidiary. We own the registered trademarks Vision Sciences®, Slide-On®, EndoSheath®, EndoWipe® and The Vision System®. Not all products referenced in this report are approved or cleared for sale, distribution, or use.
	We have two reportable segments: medical and industrial. Each of these operating segments has unique characteristics and faces different opportunities and challenges.
	Our medical segment designs, manufactures and sells our advanced line of endoscopy-based products, including our flexible endoscopes, and our EndoSheath technology referred to as a sheath or EndoSheath disposable, for a variety of specialties and markets.
	Our industrial segment, through our wholly-owned subsidiary Machida, designs, manufactures, and sells borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers or a small camera for the visual inspection of narrow cavities.  Our borescopes are used to inspect aircraft engines, cast parts and ground turbines, among other items.
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate that we will continue to incur negative cash flows from operations during fiscal 2015, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, revitalizing a research and development pipeline, and general business operations. As of March 31, 2014, we had cash and cash equivalents totaling approximately $1.2 million. We expect that our cash at March 31, 2014, together with the $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2015, under a letter agreement dated May 29, 2014 from Lewis C. Pell, our Chairman, should be sufficient to fund our operations through at least March 31, 2015. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitment under the Letter Agreement becomes unavailable or expires, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
Consolidation, Policy [Policy Text Block]	'								'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vision-Sciences, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	'								'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant of which relate to the allowance for doubtful accounts, market value for inventories, warranties, and fair value of equity based instruments. Actual results could differ from those estimates.
Revenue Recognition, Policy [Policy Text Block]	'								'
	Revenue Recognition
	We recognize revenue in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 605 (Topic 605, Revenue Recognition). ASC 605 requires that five basic criteria must be met before revenue can be recognized:
		1	persuasive evidence that an arrangement exists;
		2	delivery has occurred or services were rendered;
		3	the fee is fixed and determinable;
		4	collectability is reasonably assured; and
		5	the fair value of undelivered elements, if any, exists.
	Determination of criterion (4) above is based on management’s judgment regarding the collectability of invoices for products and services delivered to customers. Should changes in conditions cause management to determine this criterion is not met for certain future transactions, revenue recognized for any reporting period could be adversely affected. We recognize revenue when title passes to the customer, generally upon shipment of our products F.O.B. shipping point. Revenue for service repairs of equipment is recognized after service has been completed, and service contract revenue is recognized ratably over the term of the contract.
	For products sold to Stryker we recognize revenue in a two-step process. The first step is recognition of revenue for our cost to manufacture these products when title passes to Stryker, generally upon shipment of our products F.O.B. shipping point. The second step is recognition of revenue for our specified margin of Stryker’s gross profit after Stryker sells the products to its end customers, based upon reports received from Stryker monthly. There is no minimum amount of product that Stryker is required to purchase from us.
Research and Development Expense, Policy [Policy Text Block]	'								'
	Research and Development Expenses
	Costs of research, new product development, and product redesign are charged to expense as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'								'
	Stock-Based Compensation
	We account for stock-based awards issued to employees in accordance with the provisions of ASC 718 (Topic 718, Compensation – Stock Compensation). We recognize stock-based compensation expense on a straight-line uniform basis over the requisite service period of the award, which is generally four years for employees. We use historical data to estimate expected employee behaviors related to option exercises and forfeitures and include these expected forfeitures as a part of the estimate of stock-based compensation expense as of the grant date. For stock-based awards with performance-based vesting conditions, we are also required to estimate the probability of the vesting conditions being met. Stock-based awards issued to consultants are accounted for in accordance with the provisions of ASC 718 and ASC 505-50 (Subtopic 50 “Equity-Based Payments to Non-Employees” of Topic 505, Equity). Options granted to consultants are periodically revalued as the options vest, and are recognized as an expense over the related period of service or the vesting period, whichever is longer. Under the provisions of ASC 718, members of the Board are considered employees for calculation of stock-based compensation expense.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'								'
	Foreign Currency Transactions
	We charge foreign currency transaction gains or losses in connection with our purchases of products from foreign vendors to operations. For each of the fiscal years presented these amounts were immaterial.
Income Tax, Policy [Policy Text Block]	'								'
	Income Taxes
	We account for income taxes in accordance with the provisions of ASC 740 (Topic 740, Income Taxes). ASC 740 prescribes that the use of the liability method be used for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized.
	ASC Topic 740 also clarifies the accounting for uncertainty in income taxes recognized in the financial statements. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return.
	Additionally, ASC Topic 740 provides guidance on the recognition of interest and penalties related to income taxes. We have elected to treat interest and penalties, to the extent they arise, as a component of selling, general, and administrative expenses.
Earnings Per Share, Policy [Policy Text Block]	'								'
	Basic and Diluted Net Loss per Common Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding. For all periods presented, the diluted net loss per common share is the same as basic net loss per common share, as the inclusion of other shares of stock issuable pursuant to stock options, warrants, and convertible debt would be anti-dilutive. The following table summarizes equity securities that were excluded from the calculation of fully diluted loss per share as of March 31, 2014 and 2013:
			March 31,
			2014			2013
	Convertible debt			20,599,250			14,166,667
	Stock options			4,377,874			5,780,608
	Warrants			1,880,620			1,880,620
	Restricted stock			1,325,402			122,044
	Total anti-dilutive securities			28,183,146			21,949,939
Cash and Cash Equivalents, Policy [Policy Text Block]	'								'
	Cash and Cash Equivalents
	We classify investments with original maturities of 90 days or less, consisting of certificates of deposits and a money market account at a bank, as cash equivalents. Cash and cash equivalents consisted of cash and money market accounts at March 31, 2014 and 2013.
Fair Value Measurement, Policy [Policy Text Block]	'								'
	Fair Value Measurements
	The carrying amounts reflected in our consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses, accrued compensation, and capital lease obligations approximate fair value due to their short-term nature. The carrying value of our convertible debt-related party approximates fair value due to its attributes which include, amongst others, interest and its conversion feature into our common stock.
	In determining the fair value of the convertible debt – related party, we analyzed its attributes (coupon rate, conversion price, and the percentage of market cap the face value of the debt instrument was prior to the announcement of the debt) as compared to public company convertible debt issuances for an eleven (11) to sixteen (16) month period in the healthcare industry. We determined the convertible debt was not issued at a discount as its fair value was equal to its face (carrying) value.
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	'								'
	Allowance for Doubtful Accounts
	We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. This allowance is used to report trade receivables at estimated net realizable value. We rely on prior experience to estimate cash that ultimately will be collected from the gross receivables balance at period-end. We maintain a specific allowance for customer accounts that will likely not be collectible due to customer liquidity issues. We also maintain an allowance for estimated future collection losses on existing receivables, determined based on historical trends.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'								'
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivable relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.
	The following table summarizes net sales to our significant customers, which accounted for more than 10% of total segment net sales:
			Fiscal Year Ended March 31,
			2014			2013
	Medical segment
	Stryker		$	4,911		$	3,052
	Percentage of total segment net sales			35	%		26	%
	Percentage of total net sales			29	%		20	%
	Percentage of total accounts receivable, net			27	%		41	%
	Industrial segment
	Pratt & Whitney, a division of United Technology Corporation		$	527		$	944
	Percentage of total segment net sales			18	%		26	%
	Percentage of total net sales			3	%		6	%
	Percentage of accounts receivable, net			9	%		2	%
Inventory, Policy [Policy Text Block]	'								'
	Inventories
	Inventories are stated at the lower of cost or market using the first-in, first-out (“FIFO”) method. If cost exceeds market, inventory is reported at its estimated fair market value based upon our historical experience with inventory becoming obsolete due to age, changes in technology, and other factors. We record a write-down for inventories of components that have become obsolete, slow moving, or are in excess of anticipated demand or net realizable value. We perform a detailed review of inventory each fiscal quarter that considers multiple factors, including demand forecasts, product life cycle status, product development plans, and current sales levels. Inventories consist of the following:
			March 31,
			2014			2013
	Raw materials		$	3,456		$	4,352
	Work in process			329			427
	Finished goods			409			379
	Inventories, net		$	4,194		$	5,158
	Raw materials include components purchased from independent suppliers. Most purchased components are available from multiple sources, with the exception of certain key components that are supplied to us by key suppliers, with whom we have long-term supply arrangements, but no long-term supply agreements.
Property, Plant and Equipment, Policy [Policy Text Block]	'								'
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Additions and improvements are capitalized, while maintenance and repairs are expensed as incurred. Asset and accumulated depreciation accounts are relieved for dispositions, with resulting gains or losses reflected in the statement of operations. Certain products used as sales demonstration and service loaner equipment are transferred from inventory to machinery and equipment and depreciated over 3 years.
	Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives of the various assets, or for leasehold improvements, over the term of the lease, if shorter. The estimated useful lives for each major asset classification are as follows:
	Asset Classification		Estimated Useful Life
	Machinery and equipment		7 - 15 years
	Demo equipment		3 years
	Furniture and fixtures		5 years
	Leasehold improvements		lesser of lease period or 10 years
	Intangible assets		6 - 15 years
	Depreciation and amortization expense was $695 thousand and $795 thousand in fiscal years 2014 and 2013, respectively.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	'								'
	Other Assets
	Other assets consist primarily of deposits and patents. Patents are amortized on a straight-line basis over a period of up to 15 years. Our patents became fully amortized during the fiscal year ended March 31, 2012.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'								'
	Long-Lived Assets
	We review the carrying values of our long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. We believe that the carrying value of these assets is fully realizable at March 31, 2014 and 2013.
Deferred Charges, Policy [Policy Text Block]	'								'
	Deferred Debt Cost
	We defer costs, including the fair value of commitment warrants, associated with securing a line of credit or revolving loan agreement over the applicable term to maturity of the agreement. These costs are amortized as debt cost expense in our consolidated statement of operations. The costs are amortized over the term of the line of credit or revolving loan agreement on a straight-line basis or using the effective interest method.
	The following table summarizes the components of gross and net deferred debt cost balances as of March 31, 2013, which was fully amortized upon the extinguishment of the debt in fiscal 2013:
			March 31,
	Deferred debt cost		2014			2013
	Gross carrying amount		$	-		$	2,060
	Accumulated amortization			-			(816	)
	Extinguishment of debt			-			(1,244	)
	Net carrying amount		$	-		$	-
Derivatives, Policy [Policy Text Block]	'								'
	Beneficial Conversion Feature
	We account for potentially beneficial conversion features in accordance with the provisions of ASC 470-20 (Subtopic 20 “Debt with Conversions and Other Options” of Topic 470, Debt). A beneficial conversion feature exists if the fair value of the underlying common stock increases above the conversion price of the instrument on the commitment date. The difference in the common stock and conversion prices potentially results in a benefit conversion feature, a nondetachable conversion feature that is in the money at the commitment date. This resulting benefit is recorded as a convertible debt discount, with a corresponding increase to additional paid-in capital, and amortized using the effective interest method over the period from the commitment date (borrowing date) to the maturity date of the convertible debt.
Standard Product Warranty, Policy [Policy Text Block]	'								'
	Warranty Obligations
	We provide warranty on all of our products. We estimate the costs that may be incurred under warranties and record a liability in the amount of such costs at the time the product is sold. Factors that affect our warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and cost per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Warranty expense is recorded in cost of sales in our statement of operations.
	The following table summarizes changes in our warranty reserve for fiscal years 2014 and 2013:
			March 31,
			2014			2013
	Warranty reserve at April 1		$	280		$	303
	Warranties accrued during the fiscal year			60			230
	Warranties settled during the fiscal year			(110	)		(253	)
	Warranty reserve at March 31		$	230		$	280
	The warranty reserve at March 31, 2014 and 2013 is included in accrued expenses in our consolidated balance sheets.
Proceeds from Issuance of Common Stock	$0								$878,000

Note_1_The_Company_and_Summary1

Note 1 - The Company and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		March 31,
		2014			2013
	Convertible debt		20,599,250			14,166,667
	Stock options		4,377,874			5,780,608
	Warrants		1,880,620			1,880,620
	Restricted stock		1,325,402			122,044
	Total anti-dilutive securities		28,183,146			21,949,939
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	'
		Fiscal Year Ended March 31,
		2014			2013
	Medical segment
	Stryker	$	4,911		$	3,052
	Percentage of total segment net sales		35	%		26	%
	Percentage of total net sales		29	%		20	%
	Percentage of total accounts receivable, net		27	%		41	%
	Industrial segment
	Pratt & Whitney, a division of United Technology Corporation	$	527		$	944
	Percentage of total segment net sales		18	%		26	%
	Percentage of total net sales		3	%		6	%
	Percentage of accounts receivable, net		9	%		2	%
Schedule of Inventory, Current [Table Text Block]	'
		March 31,
		2014			2013
	Raw materials	$	3,456		$	4,352
	Work in process		329			427
	Finished goods		409			379
	Inventories, net	$	4,194		$	5,158
Property, Plant and Equipment [Table Text Block]	'
	Asset Classification	Estimated Useful Life
	Machinery and equipment	7 - 15 years
	Demo equipment	3 years
	Furniture and fixtures	5 years
	Leasehold improvements	lesser of lease period or 10 years
	Intangible assets	6 - 15 years
Schedule of Deferred Debt Cost [Table Text Block]	'
		March 31,
	Deferred debt cost	2014			2013
	Gross carrying amount	$	-		$	2,060
	Accumulated amortization		-			(816	)
	Extinguishment of debt		-			(1,244	)
	Net carrying amount	$	-		$	-
Schedule of Product Warranty Liability [Table Text Block]	'
		March 31,
		2014			2013
	Warranty reserve at April 1	$	280		$	303
	Warranties accrued during the fiscal year		60			230
	Warranties settled during the fiscal year		(110	)		(253	)
	Warranty reserve at March 31	$	230		$	280

Note_2_Segment_Information_Tab

Note 2 - Segment Information (Tables)	12 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	Fiscal Year Ended March 31,	Medical			Industrial			Adjustments*			Consolidated
	2014
	Net sales	$	14,133		$	2,975		$	-		$	17,108
	Gross profit		3,469			1,029			-			4,498
	Operating loss		(7,435	)		(9	)		-			(7,444	)
	Depreciation and amortization		684			11			-			695
	Assets		11,243			1,775			(2,185	)		10,833
	Expenditures for fixed assets		53			-			-			53
	2013
	Net sales	$	11,630		$	3,657		$	-		$	15,287
	Gross profit		3,102			1,240			-			4,342
	Operating loss		(8,381	)		(96	)		-			(8,477	)
	Depreciation and amortization		772			23			-			795
	Assets		11,833			1,466			(1,922	)		11,377
	Expenditures for fixed assets		95			-			-			95
Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]	'
		March 31,
	*Adjustments	2014			2013
	Intercompany eliminations	$	(1,499	)	$	(1,236	)
	Investment in subsidiaries		(686	)		(686	)
	Total adjustments	$	(2,185	)	$	(1,922	)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	'
		Fiscal Year Ended March 31,
		2014			2013
	Operating loss	$	(7,444	)	$	(8,477	)
	Interest expense, net		(191	)		(499	)
	Debt cost expense		(43	)		(272	)
	Loss on extinguishment of debt		-			(1,244	)
	Other, net		(24	)		(53	)
	Loss before provision for income taxes	$	(7,702	)	$	(10,545	)
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
		Fiscal Year Ended March 31,
		2014						2013
	United States	$	11,435			67	%	$	10,296			67	%
	Europe		4,642			27	%		3,527			23	%
	Asia and Australia		349			2	%		345			2	%
	Canada		274			2	%		471			3	%
	Middle East and Africa		254			1	%		468			3	%
	Central and South America		154			1	%		180			2	%
	Net sales	$	17,108			100	%	$	15,287			100	%

Note_3_Income_Taxes_Tables

Note 3 - Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		Fiscal Year Ended March 31,
		2014			2013
	Federal statutory rate		-34	%		-34	%
	State taxes, net of federal tax benefit		-6	%		--	%
	Permanent differences:
	Incentive stock options		2	%		2	%
	Effect of permanent differences		2	%		2	%
	Increase in valuation allowance		38	%		32	%
	Effective tax rate		--	%		--	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		March 31,
		2014			2013
	Net operating loss carryforwards	$	26,884		$	24,310
	Stock-based compensation		3,136			2,898
	Nondeductible reserves		224			248
	Depreciation and amortization		208			143
	Capital loss carryforwards		7			7
	Other		366			352
	Gross deferred tax asset		30,825			27,958
	Valuation allowance		(30,825	)		(27,958	)
	Net deferred tax asset	$	-		$	-

Note_4_Accrued_Expenses_Tables

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		March 31,
		2014		2013
	Interest payable—related party	$	253	$	70
	Warranty reserve		230		280
	Accrued accounts payable		108		63
	Accrued other		96		75
	Accrued accounting fees		90		100
	Accrued legal fees		77		41
	Sales tax payable		33		27
	Accrued travel expenses		31		72
	Accrued expenses	$	918	$	728

Note_6_Convetible_Debt_Related1

Note 6 - Convetible Debt - Related Party (Tables)	12 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Convertible Debt—Related Party	Gross		Unamortized			Net
		Principal		Debt			Amount
		Amount		Discount			Outstanding
		Outstanding
	Replacement Note	$	20,000	$	-		$	20,000
	2013 Note		3,500		(1,086	)		2,414
		$	23,500	$	(1,086	)	$	22,414
Convertible Debt [Table Text Block]	'
	Date	Borrowing		Convertible			Share		Gross
		Amount		Shares			Price on		Beneficial
							Borrowing		Conversion
							Date		Feature
	7-Oct-13	$	1,000		1,123,595		$	0.95	$	67
	26-Nov-13		1,000		1,123,595			1.01		135
	21-Jan-14		1,000		1,123,595			1.39		562
	13-Mar-14		500		561,799			1.54		365
		$	3,500		3,932,584				$	1,129
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	'
		Fiscal Year Ended
		March 31,
		2014		2013
	Debt cost expense	$	43	$	272
	Interest expense		183		488

Note_7_Commitments_and_Conting1

Note 7 - Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Operating Leases of Lessee Disclosure [Table Text Block]	'
	Fiscal Year Ending March 31,	Office		Capital
		Lease		Lease
		Commitments		Obligations
	2015	$	471	$	22
	2016		196		-
	Total future minimum lease payments	$	667		22
	Less—amount representing interest				-
	Present value of future payments			$	22

Note_8_Common_Stock_Tables

Note 8 - Common Stock (Tables)	12 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Common Stock Issued and Cash Received in Purchase Agreement	'
	Month	Description	Number of		Share		Gross
			Shares of		Price		Proceeds
			Common Stock
			Issued
	Apr-12	Initial purchase shares		599,880	$	1.667	$	1,000
	Apr-12	Initial commitment shares		160,000		-		-
	Apr-12	Initial additional commitment shares (1)		15,333		-		-
				775,213			$	1,000

Note_9_StockBased_Awards_Table

Note 9 - Stock-Based Awards (Tables)	12 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Fiscal Year Ended March 31,
			2014								2013
			Number				Weighted				Number				Weighted
			of Shares				Average				of Shares				Average
							Exercise								Exercise
							Price								Price
	Outstanding at April 1			5,780,608			$	2.09				6,007,661			$	2.23
	Granted			1,096,500				1.04				1,019,750				1.25
	Exercised			-				-				(87,881	)			1.13
	Cancelled (1)			(2,499,234	)			2.19				(1,158,922	)			2.18
	Outstanding at March 31			4,377,874			$	1.78				5,780,608			$	2.09
	Vested and expected to vest at March 31			4,302,138			$	1.79				5,622,126			$	2.1
	Exercisable at March 31			3,531,403			$	1.9				3,580,173			$	2.34
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
						Stock Options Outstanding											Stock Options Exercisable
	Range of Exercise Prices					Number				Weighted				Weighted			Number		Weighted
						of Shares				Average				Exercise			of Shares		Average
										Remaining				Average					Exercise
										Contractual Life				Price					Price
	$0.79	-	$1.16				1,591,250				8.07			$	1			994,500	$	1
	$1.17	-	$2.32				1,868,399				4.88			$	1.64			1,710,586	$	1.62
	$2.33	-	$3.48				464,350				6.63			$	2.63			372,442	$	2.65
	$3.49	-	$4.65				293,375				1.23			$	3.93			293,375	$	3.93
	$4.66	-	$5.81				160,500				4.16			$	4.88			160,500	$	4.88
							4,377,874				5.96			$	1.78			3,531,403	$	1.9
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
			Fiscal Year Ended March 31,
			2014								2013
							Weighted								Weighted
							Average								Average
			Number				Grant				Number				Grant
			of Shares				Price				of Shares				Price
	Nonvested at April 1			122,044			$	2.37				306,606			$	2.5
	Granted			1,365,000				1				40,000				1.4
	Vested			(161,642	)			1.54				(174,284	)			2.3
	Forfeited			-				-				(50,278	)			2.66
	Nonvested at March 31			1,325,402			$	1.06				122,044			$	2.37
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
			Fiscal Year Ended March 31,
			2014				2013
	Risk-free interest rate			1.27	%			1.05	%
	Expected life (in years)			5.47				6.43
	Expected volatility			79	%			84	%
	Expected dividend yield			--				--
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
			Fiscal Year Ended March 31,
			2014				2013
	Cost of sales		$	54			$	89
	Selling, general, and administrative expenses(1)			577				1,329
	Research and development expenses			63				51
	Total stock-based compensation		$	694			$	1,469

Note_10_Treasury_Stock_Tables

Note 10 - Treasury Stock (Tables)	12 Months Ended
	Mar. 31, 2014
Disclosure Text Block Supplement [Abstract]	'
Class of Treasury Stock [Table Text Block]	'
		Number				Weighted
		of Shares				Average
	Fiscal Year Ended	Repurchased		Cost		Purchase Price
	31-Mar-14		25,525	$	28	$	1.11
	31-Mar-13		27,329	$	36	$	1.32

Note_12_Quarterly_Financial_Da1

Note 12 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Mar. 31, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
		Fiscal Year Ended March 31, 2014
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter			Total
	Net sales	$	3,652		$	3,968		$	4,507		$	4,981		$	17,108
	Gross profit	$	1,080		$	1,195		$	1,378		$	845		$	4,498
	Net loss	$	(2,434	)	$	(1,323	)	$	(1,562	)	$	(2,395	)	$	(7,714	)
	Net loss per common share - basic and diluted	$	(0.05	)	$	(0.03	)	$	(0.03	)	$	(0.05	)	$	(0.17	)
		Fiscal Year Ended March 31, 2013
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter			Total
	Net sales	$	3,396		$	3,739		$	3,952		$	4,200		$	15,287
	Gross profit	$	913		$	1,070		$	1,132		$	1,227		$	4,342
	Net loss	$	(2,647	)	$	(4,264	)	$	(1,577	)	$	(2,069	)	$	(10,557	)
	Net loss per common share - basic and diluted	$	(0.06	)	$	(0.09	)	$	(0.03	)	$	(0.04	)	$	(0.23	)

Note_1_The_Company_and_Summary2

Note 1 - The Company and Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Note 1 - The Company and Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Number of Reportable Segments	2	'	'
Cash and Cash Equivalents, at Carrying Value	$1,237,000	$788,000	$2,674,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	'4 years	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'
Depreciation, Depletion and Amortization	695,000	795,000	'
Finite-Lived Intangible Asset, Useful Life	'15 years	'	'
Board of Directors Chairman [Member]	'	'	'
Note 1 - The Company and Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Long Term Debt Maximum Amount Lender Agreed To Provide Financial Assistance	$5,000,000	'	'

Note_1_The_Company_and_Summary3

Note 1 - The Company and Summary of Significant Accounting Policies (Details) - Equity Securities Excluded from the Calculation of Fully Diluted Loss Per Share	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive Securities	28,183,146	21,949,939
Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive Securities	20,599,250	14,166,667
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive Securities	4,377,874	5,780,608
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive Securities	1,880,620	1,880,620
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive Securities	1,325,402	122,044

Note_1_The_Company_and_Summary4

Note 1 - The Company and Summary of Significant Accounting Policies (Details) - Significant Customers (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013
Medical segment	'	'	'	'	'	'	'	'	'	'
Segment, net sales (in Dollars)	$4,981	$4,507	$3,968	$3,652	$4,200	$3,952	$3,739	$3,396	$17,108	$15,287
Stryker [Member] | Medical [Member] | Customer Concentration Risk [Member] | Sales Revenue, Segment [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segement, concentration risk	'	'	'	'	'	'	'	'	35.00%	26.00%
Stryker [Member] | Medical [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segement, concentration risk	'	'	'	'	'	'	'	'	29.00%	20.00%
Stryker [Member] | Medical [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segement, concentration risk	'	'	'	'	'	'	'	'	27.00%	41.00%
Stryker [Member] | Medical [Member] | Customer Concentration Risk [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segment, net sales (in Dollars)	'	'	'	'	'	'	'	'	4,911	3,052
Pratt & Whitney [Member] | Industrial [Member] | Customer Concentration Risk [Member] | Sales Revenue, Segment [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segement, concentration risk	'	'	'	'	'	'	'	'	18.00%	26.00%
Pratt & Whitney [Member] | Industrial [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segement, concentration risk	'	'	'	'	'	'	'	'	3.00%	6.00%
Pratt & Whitney [Member] | Industrial [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segement, concentration risk	'	'	'	'	'	'	'	'	9.00%	2.00%
Pratt & Whitney [Member] | Industrial [Member] | Customer Concentration Risk [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segment, net sales (in Dollars)	'	'	'	'	'	'	'	'	527	944
Medical [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segment, net sales (in Dollars)	'	'	'	'	'	'	'	'	14,133	11,630
Industrial [Member]	'	'	'	'	'	'	'	'	'	'
Medical segment	'	'	'	'	'	'	'	'	'	'
Segment, net sales (in Dollars)	'	'	'	'	'	'	'	'	$2,975	$3,657

Note_1_The_Company_and_Summary5

Note 1 - The Company and Summary of Significant Accounting Policies (Details) - Inventories (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$3,456	$4,352
Work in process	329	427
Finished goods	409	379
Inventories, net	$4,194	$5,158

Note_1_The_Company_and_Summary6

Note 1 - The Company and Summary of Significant Accounting Policies (Details) - Estimated Useful Life for Each Major Asset Classification	12 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment	'3 years
Intangible assets	'15 years
Machinery and Equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment	'7 years
Machinery and Equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment	'15 years
Demo Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment	'3 years
Furniture and Fixtures [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment	'5 years
Leasehold Improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment	'10 years
Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Intangible assets	'6 years
Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Intangible assets	'15 years

Note_1_The_Company_and_Summary7

Note 1 - The Company and Summary of Significant Accounting Policies (Details) - Deferred Debt (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013
Deferred Debt [Abstract]	'
Gross carrying amount	$2,060
Accumulated amortization	-816
Extinguishment of debt	($1,244)

Note_1_The_Company_and_Summary8

Note 1 - The Company and Summary of Significant Accounting Policies (Details) - Warranty Reserve (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Warranty Reserve [Abstract]	'	'
Warranty reserve	$280	$303
Warranties accrued during the fiscal year	60	230
Warranties settled during the fiscal year	-110	-253
Warranty reserve	$230	$280

Note_2_Segment_Information_Det

Note 2 - Segment Information (Details)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Note 2 - Segment Information (Details) [Line Items]	'	'
Number of Reportable Segments	2	'
Geographic Concentration Risk [Member] | UNITED KINGDOM | Sales Revenue, Net [Member]	'	'
Note 2 - Segment Information (Details) [Line Items]	'	'
Concentration Risk, Percentage	14.00%	'
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member]	'	'
Note 2 - Segment Information (Details) [Line Items]	'	'
Concentration Risk, Percentage	100.00%	100.00%

Note_2_Segment_Information_Det1

Note 2 - Segment Information (Details) - Key Financial Highlights by Reportable Segments (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013
2014	'	'	'	'	'	'	'	'	'	'
Net sales	$4,981	$4,507	$3,968	$3,652	$4,200	$3,952	$3,739	$3,396	$17,108	$15,287
Gross profit	845	1,378	1,195	1,080	1,227	1,132	1,070	913	4,498	4,342
Operating (loss) income	'	'	'	'	'	'	'	'	-7,444	-8,477
Depreciation and amortization	'	'	'	'	'	'	'	'	695	795
Assets	10,833	'	'	'	11,377	'	'	'	10,833	11,377
Expenditures for fixed assets	'	'	'	'	'	'	'	'	53	95
Medical [Member]	'	'	'	'	'	'	'	'	'	'
2014	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	14,133	11,630
Gross profit	'	'	'	'	'	'	'	'	3,469	3,102
Operating (loss) income	'	'	'	'	'	'	'	'	-7,435	-8,381
Depreciation and amortization	'	'	'	'	'	'	'	'	684	772
Assets	11,243	'	'	'	11,833	'	'	'	11,243	11,833
Expenditures for fixed assets	'	'	'	'	'	'	'	'	53	95
Industrial [Member]	'	'	'	'	'	'	'	'	'	'
2014	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	2,975	3,657
Gross profit	'	'	'	'	'	'	'	'	1,029	1,240
Operating (loss) income	'	'	'	'	'	'	'	'	-9	-96
Depreciation and amortization	'	'	'	'	'	'	'	'	11	23
Assets	1,775	'	'	'	1,466	'	'	'	1,775	1,466
Adjustments [Member]	'	'	'	'	'	'	'	'	'	'
2014	'	'	'	'	'	'	'	'	'	'
Assets	($2,185)	'	'	'	($1,922)	'	'	'	($2,185)	($1,922)

Note_2_Segment_Information_Det2

Note 2 - Segment Information (Details) - Reportable Segment Adjustments (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Reportable Segment Adjustments [Abstract]	'	'
Intercompany eliminations	($1,499)	($1,236)
Investment in subsidiaries	-686	-686
Total adjustments	($2,185)	($1,922)

Note_2_Segment_Information_Det3

Note 2 - Segment Information (Details) - Reconciliation to Loss Before Provision for Income Taxes (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Reconciliation to Loss Before Provision for Income Taxes [Abstract]	'	'
Operating loss	($7,444)	($8,477)
Interest expense, net	-191	-499
Debt cost expense	-43	-272
Loss on extinguishment of debt	'	-1,244
Other, net	-24	-53
Loss before provision for income taxes	($7,702)	($10,545)

Note_2_Segment_Information_Det4

Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013
Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	$4,981	$4,507	$3,968	$3,652	$4,200	$3,952	$3,739	$3,396	$17,108	$15,287
Geographic Concentration Risk [Member] | UNITED STATES | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	11,435	10,296
Percentage of net sales	'	'	'	'	'	'	'	'	67.00%	67.00%
Geographic Concentration Risk [Member] | Europe [Member] | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	4,642	3,527
Percentage of net sales	'	'	'	'	'	'	'	'	27.00%	23.00%
Geographic Concentration Risk [Member] | Asia and Australia [Member] | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	349	345
Percentage of net sales	'	'	'	'	'	'	'	'	2.00%	2.00%
Geographic Concentration Risk [Member] | CANADA | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	274	471
Percentage of net sales	'	'	'	'	'	'	'	'	2.00%	3.00%
Geographic Concentration Risk [Member] | Middle East and Africa [Member] | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	254	468
Percentage of net sales	'	'	'	'	'	'	'	'	1.00%	3.00%
Geographic Concentration Risk [Member] | Latin America [Member] | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	154	180
Percentage of net sales	'	'	'	'	'	'	'	'	1.00%	2.00%
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Segment Information (Details) - Net Sales Based on the Geographic Location of the External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	$17,108	$15,287
Percentage of net sales	'	'	'	'	'	'	'	'	100.00%	100.00%

Note_3_Income_Taxes_Details

Note 3 - Income Taxes (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Note 3 - Income Taxes (Details) [Line Items]	'	'
Unrecognized Tax Benefits	$0	$0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	0	0
Income Tax Expense (Benefit)	12,000	12,000
Valuation Allowance, Deferred Tax Asset, Change in Amount	2,900,000	'
Internal Revenue Service (IRS) [Member]	'	'
Note 3 - Income Taxes (Details) [Line Items]	'	'
Operating Loss Carryforwards	72,700,000	'
State and Local Jurisdiction [Member]	'	'
Note 3 - Income Taxes (Details) [Line Items]	'	'
Operating Loss Carryforwards	45,700,000	'
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$1,700,000	'

Note_3_Income_Taxes_Details_Re

Note 3 - Income Taxes (Details) - Reconciliation of the Effective Income Tax Rate to the Federal Statutory Rate	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Reconciliation of the Effective Income Tax Rate to the Federal Statutory Rate [Abstract]	'	'
Federal statutory rate	-34.00%	-34.00%
State taxes, net of federal tax benefit	-6.00%	'
Permanent differences:	'	'
Incentive stock options	2.00%	2.00%
Effect of permanent differences	2.00%	2.00%
Increase in valuation allowance	38.00%	32.00%

Note_3_Income_Taxes_Details_De

Note 3 - Income Taxes (Details) - Deferred Tax Assets (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Deferred Tax Assets [Abstract]	'	'
Net operating loss carryforwards	$26,884	$24,310
Stock-based compensation	3,136	2,898
Nondeductible reserves	224	248
Depreciation and amortization	208	143
Capital loss carryforwards	7	7
Other	366	352
Gross deferred tax asset	30,825	27,958
Valuation allowance	($30,825)	($27,958)

Note_4_Accrued_Expenses_Detail

Note 4 - Accrued Expenses (Details) - Accrued Liabilities (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'	'	'
Interest payable—related party	$253	$70	'
Warranty reserve	230	280	303
Accrued accounts payable	108	63	'
Accrued other	96	75	'
Accrued accounting fees	90	100	'
Accrued legal fees	77	41	'
Sales tax payable	33	27	'
Accrued travel expenses	31	72	'
Accrued expenses	$918	$728	'

Note_6_Convetible_Debt_Related2

Note 6 - Convetible Debt - Related Party (Details) (USD $)

Mar. 31, 2014

Mar. 13, 2014

Jan. 21, 2014

Nov. 26, 2013

Oct. 07, 2013

Mar. 31, 2013

Mar. 31, 2014

Sep. 25, 2013

Mar. 31, 2014

Sep. 30, 2011

Mar. 31, 2014

Sep. 19, 2012

Jul. 25, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

The 2013 Note [Member]

The 2013 Note [Member]

The 2013 Note [Member]

Replacement Note [Member]

Replacement Note [Member]

Replacement Note [Member]

Replacement Note [Member]

The Original Agreement [Member]

The Original Agreement [Member]

The Letter Agreement [Member]

Convertible Debt [Member]

Convertible Debt [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Note 6 - Convetible Debt - Related Party (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable, Related Parties

'

'

'

'

'

'

'

$3,500,000

'

'

'

'

'

'

'

'

'

Related Party Transaction, Rate

'

'

'

'

'

'

'

1.66%

'

'

0.84%

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

$1.54

$1.39

$1.01

$0.95

'

'

$0.89

'

'

$1.20

'

'

'

'

'

'

Convertible Debt

3,500,000

500,000

1,000,000

1,000,000

1,000,000

'

'

'

3,500,000

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

1,086,000

'

'

'

'

'

'

'

'

'

1,086,000

Debt Instrument, Convertible, Remaining Discount Amortization Period

'

'

'

'

'

'

'4 years 6 months

'

'

'

'

'

'

'

'

'

'

Convertible Debt, Noncurrent

22,414,000

'

'

'

'

17,000,000

'

'

'

15,000,000

'

20,000,000

'

'

'

'

'

Notes Payable, Related Parties, Additional Borrowings Increase (Decrease)

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

Due to Related Parties

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

1,880,620

'

'

'

Fair Value Assumptions, Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.86

'

'

Deferred Costs, Noncurrent

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

Accrued Liabilities, Current

918,000

'

'

'

'

728,000

'

'

'

'

253,000

'

'

'

'

'

'

Long Term Debt Maximum Amount Lender Agreed To Provide Financial Assistance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

'

Note_6_Convetible_Debt_Related3

Note 6 - Convetible Debt - Related Party (Details) - Convertible Debt-Related Party (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Sep. 19, 2012	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified			Replacement Note [Member]	Replacement Note [Member]	Replacement Note [Member]	The 2013 Note [Member]	The 2013 Note [Member]	The 2013 Note [Member]	Gross Amount [Member]	Convertible Debt [Member]	Net Amount [Member]
			Gross Amount [Member]	Net Amount [Member]		Gross Amount [Member]	Convertible Debt [Member]	Net Amount [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Gross Principal Amount Outstanding	$22,414	$17,000	$20,000	$20,000	$20,000	$3,500	'	$2,414	$23,500	'	$22,414
Unamortized Debt Discount	'	'	'	'	'	'	-1,086	'	'	-1,086	'
Net Amount Outstanding	$22,414	$17,000	$20,000	$20,000	$20,000	$3,500	'	$2,414	$23,500	'	$22,414

Note_6_Convetible_Debt_Related4

Note 6 - Convetible Debt - Related Party (Details) - Beneficial Conversion Feature Amounts (USD $)	0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 13, 2014	Jan. 21, 2014	Oct. 07, 2013	Nov. 26, 2013	Mar. 31, 2014
Beneficial Conversion Feature Amounts [Abstract]	'	'	'	'	'
Borrowing Amount	$500	$1,000	$1,000	$1,000	$3,500
Convertible Shares	561,799	1,123,595	1,123,595	1,123,595	3,932,584
Share Price (in Dollars per share)	$1.54	$1.39	$0.95	$1.01	'
Gross Beneficial Conversion Feature	$365	$562	$67	$135	$1,129

Note_6_Convetible_Debt_Related5

Note 6 - Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Note 6 - Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings [Line Items]	'	'
Debt cost expense	$43	$272
Interest expense	192	503
Related Party [Member]	'	'
Note 6 - Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings [Line Items]	'	'
Interest expense	$183	$488

Note_7_Commitments_and_Conting2

Note 7 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Note 7 - Commitments and Contingencies (Details) [Line Items]	'	'
Operating Leases, Rent Expense	$488	$496
Orangeburg Facility [Member]	'	'
Note 7 - Commitments and Contingencies (Details) [Line Items]	'	'
Area of Real Estate Property	20,500	'
Natick Facility [Member]	'	'
Note 7 - Commitments and Contingencies (Details) [Line Items]	'	'
Area of Real Estate Property	9,835	'

Note_7_Commitments_and_Conting3

Note 7 - Commitments and Contingencies (Details) - Future Minimum Lease Commitments (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Future Minimum Lease Commitments [Abstract]	'
2015	$471
2015	22
2016	196
Total future minimum lease payments	667
Total future minimum lease payments	22
Present value of future payments	$22

Note_8_Common_Stock_Details

Note 8 - Common Stock (Details) (USD $)	1 Months Ended	12 Months Ended		25 Months Ended
	Apr. 27, 2012	Mar. 31, 2014	Mar. 31, 2013	Apr. 27, 2014	Jul. 26, 2012
Note 8 - Common Stock (Details) [Line Items]	'	'	'	'	'
Maximum Amount Common Stock Available to Sell in Purchase Agreement	$15,000,000	$21,000,000	'	'	'
Common Stock, Other Value, Outstanding	75,000,000	'	'	'	'
Fair Value Assumptions, Expected Term	'	'	'	'3 years	'
Sale of Stock, Price Per Share (in Dollars per share)	'	'	'	'	$3
Proceeds from Sale of Treasury Stock	1,000,000	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	175,333	'	'	'	'
Stock Issued During Period, Shares, Conversion of Convertible Securities (in Shares)	'	230,000	'	'	'
Debt Issuance Cost	'	122,000	'	'	'
Proceeds from Issuance of Common Stock	'	0	878,000	'	'
Commitment Shares [Member]	'	'	'	'	'
Note 8 - Common Stock (Details) [Line Items]	'	'	'	'	'
Stock Issued During Period, Value, Conversion of Convertible Securities	'	1,000,000	'	'	'
Lincoln Park Capital Fund, LLC [Member]	'	'	'	'	'
Note 8 - Common Stock (Details) [Line Items]	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	175,333	'	'	'	'
Maximum [Member]	'	'	'	'	'
Note 8 - Common Stock (Details) [Line Items]	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	215,000	'	'	'	'
Stock Issued During Period, Value, Conversion of Convertible Securities	'	$15,000,000	'	'	'

Note_8_Common_Stock_Details_Co

Note 8 - Common Stock (Details) - Common Stock Issued and Cash Received in Connection with Purchase Agreement (USD $)	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 27, 2012		Mar. 31, 2014	Mar. 31, 2013
Note 8 - Common Stock (Details) - Common Stock Issued and Cash Received in Connection with Purchase Agreement [Line Items]	'		'	'
Number of Shares of Common Stock Issued	775,213		47,614,000	46,249,000
Share Price (in Dollars per share)	'		$0.01	$0.01
Gross Proceeds (in Dollars)	$1,000		'	'
Initial Purchase Shares [Member]	'		'	'
Note 8 - Common Stock (Details) - Common Stock Issued and Cash Received in Connection with Purchase Agreement [Line Items]	'		'	'
Number of Shares of Common Stock Issued	599,880		'	'
Share Price (in Dollars per share)	$1.67		'	'
Gross Proceeds (in Dollars)	1,000		'	'
Initial Commitment Shares [Member]	'		'	'
Note 8 - Common Stock (Details) - Common Stock Issued and Cash Received in Connection with Purchase Agreement [Line Items]	'		'	'
Number of Shares of Common Stock Issued	160,000		'	'
Initial Additional Commitment Shares [Member]	'		'	'
Note 8 - Common Stock (Details) - Common Stock Issued and Cash Received in Connection with Purchase Agreement [Line Items]	'		'	'
Number of Shares of Common Stock Issued	15,333	[1]	'	'
Share Price (in Dollars per share)	'	[1]	'	'
Gross Proceeds (in Dollars)	'	[1]	'	'
[1]	Calculated as follows: ($1.0 million stock purchase divided by $15.0 million total maximum amount) multiplied by 230,000 additional commitment shares.

Note_9_StockBased_Awards_Detai

Note 9 - Stock-Based Awards (Details) (USD $)

12 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

28 Months Ended

30 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Nov. 26, 2013

Mar. 31, 2014

Mar. 31, 2013

Sep. 30, 2014

Dec. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Jul. 25, 2012

Aug. 15, 2003

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Annual Vesting [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Employee Stock Option [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

2000 Stock Incentive Plan [Member]

2007 Stock Incentive Plan [Member]

2007 Stock Incentive Plan [Member]

2003 Director Option Plan [Member]

2003 Director Option Plan [Member]

Cynthia F. Ansari [Member]

Katherine L. Wolf [Member]

Howard Zauberman [Member]

Howard Zauberman [Member]

Cynthia F. Ansari [Member]

Note 9 - Stock-Based Awards (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

4,500,000

7,000,000

5,000,000

'

450,000

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

1,096,500

1,019,750

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

2,499,234

[1]

1,158,922

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,125,000

612,458

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

1,415,603

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'6 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

'5 years 109 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term

'5 years 328 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

$0.68

$0.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)

$319,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

202,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value (in Dollars)

308,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)

0

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

'

'

'

1,200,000

1,365,000

40,000

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

300,000

'

161,642

174,284

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense (in Dollars)

694,000

1,469,000

'

'

'

'

'

'

289,000

577,000

[2]

1,329,000

[2]

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'

'219 days

'2 years 6 months

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options (in Dollars)

'

'

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Includes cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari (1,125,000 stock options), and our former EVP, Corporate Development and Chief Financial Officer, Katherine L. Wolf (612,458 stock options).

[2]

Reflects reversal of stock-based compensation expense of $289 thousand in fiscal 2014 for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_9_StockBased_Awards_Detai1

Note 9 - Stock-Based Awards (Details) - Stock Options Activity (USD $)	12 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Stock Options Activity [Abstract]	'		'
Outstanding - Number of Shares	5,780,608		6,007,661
Oustanding - Average Exercise price	$2.09		$2.23
Vested and expected to vest at March 31	4,302,138		5,622,126
Vested and expected to vest at March 31	$1.79		$2.10
Exercisable at March 31	3,531,403		3,580,173
Exercisable at March 31	$1.90		$2.34
Granted	1,096,500		1,019,750
Granted	$1.04		$1.25
Exercised	'		-87,881
Exercised	'		$1.13
Cancelled (1)	-2,499,234	[1]	-1,158,922
Cancelled (1)	$2.19	[1]	$2.18	[1]
Outstanding - Number of Shares	4,377,874		5,780,608
Oustanding - Average Exercise price	$1.78		$2.09
[1]	Includes cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari (1,125,000 stock options), and our former EVP, Corporate Development and Chief Financial Officer, Katherine L. Wolf (612,458 stock options).

Note_9_StockBased_Awards_Detai2

Note 9 - Stock-Based Awards (Details) - Outstanding and Exercisable Stock Options (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares (in Shares)	4,377,874
Weighted Average Remaining Contractual Life	'5 years 350 days
Weighted Average Exercise Price	$1.78
Number of Shares Exercisable (in Shares)	3,531,403
Exercisable Options Weighted Average Exercise Price	$1.90
Range 1 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Lower Exercise Price Limit	$0.79
Upper Exercise Price Limit	$1.16
Number of Shares (in Shares)	1,591,250
Weighted Average Remaining Contractual Life	'8 years 25 days
Weighted Average Exercise Price	$1
Number of Shares Exercisable (in Shares)	994,500
Exercisable Options Weighted Average Exercise Price	$1
Range 2 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Lower Exercise Price Limit	$1.17
Upper Exercise Price Limit	$2.32
Number of Shares (in Shares)	1,868,399
Weighted Average Remaining Contractual Life	'4 years 321 days
Weighted Average Exercise Price	$1.64
Number of Shares Exercisable (in Shares)	1,710,586
Exercisable Options Weighted Average Exercise Price	$1.62
Range 3 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Lower Exercise Price Limit	$2.33
Upper Exercise Price Limit	$3.48
Number of Shares (in Shares)	464,350
Weighted Average Remaining Contractual Life	'6 years 229 days
Weighted Average Exercise Price	$2.63
Number of Shares Exercisable (in Shares)	372,442
Exercisable Options Weighted Average Exercise Price	$2.65
Range 4 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Lower Exercise Price Limit	$3.49
Upper Exercise Price Limit	$4.65
Number of Shares (in Shares)	293,375
Weighted Average Remaining Contractual Life	'1 year 83 days
Weighted Average Exercise Price	$3.93
Number of Shares Exercisable (in Shares)	293,375
Exercisable Options Weighted Average Exercise Price	$3.93
Range 5 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Lower Exercise Price Limit	$4.66
Upper Exercise Price Limit	$5.81
Number of Shares (in Shares)	160,500
Weighted Average Remaining Contractual Life	'4 years 58 days
Weighted Average Exercise Price	$4.88
Number of Shares Exercisable (in Shares)	160,500
Exercisable Options Weighted Average Exercise Price	$4.88

Note_9_StockBased_Awards_Detai3

Note 9 - Stock-Based Awards (Details) - Restricted Stock Activity (Restricted Stock [Member], USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Restricted Stock [Member]	'	'
Note 9 - Stock-Based Awards (Details) - Restricted Stock Activity [Line Items]	'	'
Nonvested - Number of Shares	122,044	306,606
Nonvested - Weighted Average Grant Price	$2.37	$2.50
Granted	1,365,000	40,000
Granted	$1	$1.40
Vested	-161,642	-174,284
Vested	$1.54	$2.30
Forfeited	'	-50,278
Forfeited	'	$2.66
Nonvested - Number of Shares	1,325,402	122,044
Nonvested - Weighted Average Grant Price	$1.06	$2.37

Note_9_StockBased_Awards_Detai4

Note 9 - Stock-Based Awards (Details) - Black-Scholes Valuation Assumptions	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Black-Scholes Valuation Assumptions [Abstract]	'	'
Risk-free interest rate	1.27%	1.05%
Expected life (in years)	'5 years 171 days	'6 years 156 days
Expected volatility	79.00%	84.00%

Note_9_StockBased_Awards_Detai5

Note 9 - Stock-Based Awards (Details) - Stock-based Compensation Expense (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'
Allocated stock-based compensation expense	$694		$1,469
Cost of Sales [Member]	'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'
Allocated stock-based compensation expense	54		89
General and Administrative Expense [Member]	'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'
Allocated stock-based compensation expense	577	[1]	1,329	[1]
Research and Development Expense [Member]	'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'
Allocated stock-based compensation expense	$63		$51
[1]	Reflects reversal of stock-based compensation expense of $289 thousand in fiscal 2014 for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_10_Treasury_Stock_Details

Note 10 - Treasury Stock (Details) - Treasury Stock Activity (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Treasury Stock Activity [Abstract]	'	'
Number of Shares Repurchased	25,525	27,329
Cost	$28	$36
Weighted Average Purchase Price	$1.11	$1.32

Note_11_Employee_Savings_Plan_

Note 11 - Employee Savings Plan (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'	'
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	70.00%	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	$0	$0

Note_12_Quarterly_Financial_Da2

Note 12 - Quarterly Financial Data (Unaudited) (Details) - Quarterly Financial Data (Unaudited) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013
Quarterly Financial Data (Unaudited) [Abstract]	'	'	'	'	'	'	'	'	'	'
Net sales	$4,981	$4,507	$3,968	$3,652	$4,200	$3,952	$3,739	$3,396	$17,108	$15,287
Gross profit	845	1,378	1,195	1,080	1,227	1,132	1,070	913	4,498	4,342
Net loss	($2,395)	($1,562)	($1,323)	($2,434)	($2,069)	($1,577)	($4,264)	($2,647)	($7,714)	($10,557)
Net loss per common share - basic and diluted (in Dollars per share)	($0.05)	($0.03)	($0.03)	($0.05)	($0.04)	($0.03)	($0.09)	($0.06)	($0.17)	($0.23)